
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| INVA | Innoviva | 18.35 | -3.58 | -16.32% |
| Name | Price | % Change | |
|---|---|---|---|
| $18.35 | -16.32% |

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Piper Sandler analyst David Amsellem last night initiated coverage of Innoviva (INVA) with an Overweight rating and $29 price target The firm views Innoviva as a “unique opportunity within the

Piper Sandler initiated coverage of Innoviva (INVA) with an Overweight rating and $29 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

Oppenheimer lowered the firm’s price target on Innoviva (INVA) to $34 from $35 and keeps an Outperform rating on the shares. The firm notes Innoviva’s Q3 revenue and EBITDA missed

Reports Q3 revenue $106.1M, consensus $115.3M. “IST delivered another quarter of excellent growth, with U.S. net product sales increasing 45% year-over-year to $43.3 million, keeping us on track to achieve

Heading into the last quarter of 2026, the big question is, what’s next? The conflicts in the Middle East remain persistent, and while oil prices have climbed above $100 per

Oppenheimer assumed coverage of Innoviva (INVA) with an Outperform rating and $35 price target The market is valuing Innoviva as declining respiratory royalty company while assigning limited credit to its

Virtual Meeting to be held on August 19 hosted by Cantor Fitzgerald. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Innoviva and keeping the price target at $46.00. Ram Selvaraju has given his Buy rating due to a combination

Cantor Fitzgerald lowered the firm’s price target on Innoviva (INVA) to $34 from $36 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 3, 2027TBA | $1.30B | $0.43 | $110.52M | 0.01 | 7.22 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.